These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15229146)

  • 41. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance.
    Serlie MJ; Allick G; Groener JE; Ackermans MT; Heijligenberg R; Voermans BC; Aerts JM; Meijer AJ; Sauerwein HP
    J Clin Endocrinol Metab; 2007 Jan; 92(1):166-71. PubMed ID: 17062758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pioglitazone and mechanisms of CV protection.
    Erdmann E; Wilcox R
    QJM; 2010 Apr; 103(4):213-28. PubMed ID: 19955228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 -- results of a pilot study.
    Parhofer KG; Otto C; Geiss HC; Laubach E; Göke B
    Exp Clin Endocrinol Diabetes; 2005 Jan; 113(1):49-52. PubMed ID: 15662596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
    Pan C; Gao Y; Gao X; Li G; Luo B; Shi H; Tian H; Jia P; Lin H; Xing X; Zhao Y; Zhou L
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):388-92. PubMed ID: 12137601
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Troglitazone directly increases HDL cholesterol levels.
    Nozue T; Michishita I; Minagawa F; Genda A
    Diabetes Care; 1999 Feb; 22(2):355-6. PubMed ID: 10333957
    [No Abstract]   [Full Text] [Related]  

  • 48. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
    Liao HW; Saver JL; Wu YL; Chen TH; Lee M; Ovbiagele B
    BMJ Open; 2017 Jan; 7(1):e013927. PubMed ID: 28057658
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study.
    Sartore G; Chilelli NC; Seraglia R; Ragazzi E; Marin R; Roverso M; Cosma C; Vaccaro O; Burlina S; Lapolla A
    Acta Diabetol; 2019 May; 56(5):505-513. PubMed ID: 30740640
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pioglitazone: Hype and hope.
    Jadhav SS; Shivane VK; Lila AR; Bandgar TR; Shah NS
    J Postgrad Med; 2014; 60(3):293-6. PubMed ID: 25121371
    [No Abstract]   [Full Text] [Related]  

  • 51. Relationships between HDL-C subfractions and HbA1C levels in non-insulin-dependent diabetics.
    Rodenas S; Cuesta C; Martini C; Sanchez-Cabezudo M
    Isr J Med Sci; 1993 Dec; 29(12):797-9. PubMed ID: 8300390
    [No Abstract]   [Full Text] [Related]  

  • 52. Are thiazolidinediones a preferred drug treatment for type 2 diabetes?
    Hurren KM; Dunham MW
    Expert Opin Pharmacother; 2021 Feb; 22(2):131-133. PubMed ID: 33280446
    [No Abstract]   [Full Text] [Related]  

  • 53. Osteoprotegerin, thiazolidinediones treatment, and silent myocardial ischemia in type 2 diabetic patients.
    Sultan A; Avignon A; Galtier F; Piot C; Mariano-Goulart D; Dupuy AM; Cristol JP
    Diabetes Care; 2008 Mar; 31(3):593-5. PubMed ID: 18083791
    [No Abstract]   [Full Text] [Related]  

  • 54. Meta-analysis of trial data may support a causal role of hyperglycaemia in cancer.
    Yang XL; Ma RC; Chan JC
    Diabetologia; 2011 Mar; 54(3):709-10; author reply 711-2. PubMed ID: 21153895
    [No Abstract]   [Full Text] [Related]  

  • 55. Insulin resistance and lipid metabolism.
    Ikeoka D; Krusinova E
    Rev Assoc Med Bras (1992); 2009; 55(3):234. PubMed ID: 19629334
    [No Abstract]   [Full Text] [Related]  

  • 56. Setting the record straight on TIDE: a lost opportunity for patients with diabetes.
    Punthakee Z; Bosch J; Gerstein HC
    Diabetologia; 2013 Sep; 56(9):1884-7. PubMed ID: 23740195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice].
    Dobiásová M
    Vnitr Lek; 2006 Jan; 52(1):64-71. PubMed ID: 16526201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses.
    Fernández-Macías JC; Ochoa-Martínez AC; Varela-Silva JA; Pérez-Maldonado IN
    Arch Med Res; 2019 Jul; 50(5):285-294. PubMed ID: 31593853
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population.
    Cai G; Shi G; Xue S; Lu W
    Medicine (Baltimore); 2017 Sep; 96(37):e8058. PubMed ID: 28906400
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atherogenic index of plasma and the risk of advanced subclinical coronary artery disease beyond traditional risk factors: An observational cohort study.
    Won KB; Jang MH; Park EJ; Park HB; Heo R; Han D; Chang HJ
    Clin Cardiol; 2020 Dec; 43(12):1398-1404. PubMed ID: 32815171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.